Siegrist, Claire-Anne MD*; Lewis, Edwin M. MPH†; Eskola, Juhani MD‡; Evans, Stephen J. W. MSc§; Black, Steven B. MD∥
From the *Center for Vaccinology and Neonatal Immunology, University of Geneva, Geneva, Switzerland; †Vaccine Study Center and Division of Research, The Permanente Medical Group, Oakland, CA; ‡National Public Health Institute KTL, Helsinki, Finland; §Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London; and ∥Pediatric Infectious Diseases, Stanford University in Palo Alto California, Stanford, CA.
Accepted for publication June 28, 2007.
C.-A.S. received research grant support from Sanofi Pasteur MSD and GlaxoSmithKline for studies unrelated to HPV vaccines and has served on scientific advisory boards concerning issues unrelated to HPV vaccines. S.B.B. and E.M.L. both received research grant support from Merck and GlaxoSmithKline for studies unrelated to HPV vaccine. J.E. and S.J.W.E. have no conflicts of interest to declare.
Address for correspondence: Claire-Anne Siegrist, MD, Center for Vaccinology and Neonatal Immunology, University of Geneva, 1 Rue Michel Servet, 1211 Geneva, Switzerland. E-mail: [email protected].
doi: 10.1097/INF.0b013e318149dfea
